Welcome to our dedicated page for Usana Health Sciences SEC filings (Ticker: USNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Deferred revenue from customer incentives, multi-currency sales in Asia, and product repurchase obligations turn each USANA annual report 10-K simplified into a dense read. If you’ve searched for “USANA SEC filings explained simply,” you already know how challenging it is to locate segment margins or wellness-product growth without spending hours in footnotes.
Stock Titan’s AI steps in with line-by-line summaries, highlighting what matters in every USANA quarterly earnings report 10-Q filing, tagging risk-factor changes, and alerting you whenever a board meeting triggers a disclosure. Our engine delivers USANA 8-K material events explained within minutes of hitting EDGAR, while interactive charts power quick USANA earnings report filing analysis. Need context on incentive-driven cash flows? Click once and you’re understanding USANA SEC documents with AI instead of decoding accounting jargon.
For governance watchers, real-time pop-ups surface USANA Form 4 insider transactions real-time, plus sortable tables of USANA executive stock transactions Form 4. Compensation analysts can dive into the USANA proxy statement executive compensation sections without losing focus—our AI extracts option awards and long-term bonus targets automatically. Whether you’re screening for “USANA insider trading Form 4 transactions” before earnings or reviewing nutritional segment trends, you’ll find every filing type—10-K, 10-Q, 8-K, Form 4, S-8, and more—updated the moment they post. Stock Titan turns complex disclosures into practical insight so you can act, not sift.
USANA Health Sciences Inc. insider reports small stock sale. The company’s Chief Sales Officer filed a Form 4 disclosing the sale of 873 shares of USANA common stock on 12/10/2025. The shares were sold at a price of $21 per share, using transaction code “S,” which indicates an open market or private sale.
After this transaction, the officer beneficially owns 8,387 shares of USANA common stock in direct ownership. The filing is made by a single reporting person and does not report any derivative securities activity.
USANA Health Sciences Inc. (USNA) reported an insider stock transaction by its Chief Information Officer. On 12/10/2025, the officer sold 2,673 shares of common stock in an open market transaction at a price of $20.9506 per share, coded as a sale ("S"). After this transaction, the reporting person held 0 shares of USANA common stock in direct ownership. The filing covers only non-derivative common stock, with no derivative securities reported.
USANA Health Sciences filed a notice under Rule 144 for a planned sale of restricted common stock. The filing covers 2,673 shares of common stock, with an aggregate market value of $56,000.95, to be sold through Morgan Stanley Smith Barney LLC on the NYSE. The issuer had 18,280,857 shares of common stock outstanding. The shares were acquired from the issuer as restricted stock in several transactions dated between February 6, 2025 and July 25, 2025. The seller represents that they are not aware of any material adverse, nonpublic information about the company’s current or prospective operations.
USANA Health Sciences (USNA) Form 4: A director reported an open-market sale of common stock. On 11/10/2025, the director sold 2,000 shares (transaction code S) at a price of $19.21 per share. Following this transaction, the director beneficially owns 5,986 shares, held directly.
USANA Health Sciences reported Q3 2025 net sales of $213.7 million, up 6.7% year over year, driven by the addition of the Hiya direct‑to‑consumer business ($30.8 million) and growth in “Other,” which offset declines in direct selling.
The quarter showed a net loss of $6.5 million versus earnings of $10.6 million a year ago. Management cites a sharp increase in the annualized effective tax rate to 65% and higher selling, general and administrative costs, including amortization of acquired intangibles and elevated marketing at Hiya. Gross margin was 77.2% (down 320 bps), reflecting Hiya’s lower gross margin mix and higher “Other.”
Direct selling net sales fell as active customers decreased to 388,000, with broad softness across Asia Pacific and Americas/Europe. Cash and cash equivalents were $145.3 million and there was no balance on the $75 million revolver at quarter‑end. Year to date, USANA repurchased 927,000 shares for $27.7 million, leaving $34.0 million authorized. As of October 31, 2025, shares outstanding were 18,280,857. Subsequently, the company initiated a cost alignment program with an expected $4.7 million one‑time Q4 charge.
USANA Health Sciences (USNA) director reported a sale of 1,057 shares of common stock (Code S) at $21.4799 on 11/03/2025. Following the transaction, the director beneficially owned 0 shares, held as direct ownership (D).
USANA Health Sciences (USNA) reported an insider transaction on a Form 4. A company director sold 1,750 shares of Common Stock on 10/31/2025 at a price of $19.79 per share (transaction code: S for open-market sale). After this trade, the insider directly beneficially owns 4,565 shares.
USANA Health Sciences (USNA) — director Form 4 activity. On 10/23/2025, 1,057 shares of common stock were acquired via the vesting/settlement of restricted stock units (code M). To cover taxes, 606 shares were withheld/disposed at $20.63 (code F). Following these transactions, the director directly owned 4,586 shares. The related RSU award had a $0 exercise price and continues to vest in scheduled 25% installments on specified dates.
USANA Health Sciences (USNA) reported an insider transaction by a director on 10/23/2025. The filing shows the conversion of restricted stock units into 1,057 shares of common stock (Transaction Code M) and a separate Code F disposition of 265 shares at $20.63 per share.
Following these transactions, the reporting person directly held 9,027 shares of common stock and 2,115 restricted stock units. The RSUs vest in four 25% installments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences (USNA) reported an insider stock acquisition by a director. On 10/23/2025, the director acquired 1,057 shares of common stock through the settlement of restricted stock units, coded M (derivative conversion).
The shares were delivered at a stated price of $0. Following the transaction, the director beneficially owns 7,986 shares directly, with 2,115 RSUs remaining outstanding. Each RSU represents the right to receive one share of USNA common stock. The RSUs vest in four 25% installments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
FAQ
What is the current stock price of Usana Health Sciences (USNA)?
What is the market cap of Usana Health Sciences (USNA)?
